Patents by Inventor Romain Wolf

Romain Wolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200392132
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: June 30, 2020
    Publication date: December 17, 2020
    Applicant: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20190218217
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 18, 2019
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20190040061
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: October 17, 2018
    Publication date: February 7, 2019
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20180265509
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 20, 2018
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Patent number: 9949979
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: April 24, 2018
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Antonio Fernandes Gomes Dos Santos, Pascal Furet, Christina Hebach, Klemens Hoegenauer, Gregory Hollingworth, Christoph Kalis, Ian Lewis, Alexander Baxter Smith, Nicolas Soldermann, Frederic Stauffer, Ross Strang, Frank Stowasser, Nicola Tuffilli, Anette Von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20170267678
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Applicant: Novartis AG
    Inventors: Nigel Graham COOKE, Paulo Fernandes Gomes Dos Santos, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frank STOWASSER, Ross Sinclair STRANG, Nicola TUFILLI, Anette von MATT, Romain WOLF, Frederic ZECRI
  • Patent number: 9763952
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 19, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Publication number: 20170022199
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: Novartis AG
    Inventors: Nigel Graham COOKE, Antonio Paulo Fernandes Gomes Dos Santos, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolaus SOLDERMANN, Frank STOWASSER, Ross Sinclair STRANG, Nicola TUFILLI, Anette von MATT, Romain WOLF, Frederic ZECRI
  • Patent number: 9539260
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 10, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9499536
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Frédèric Zecri, Nicolas Soldermann, Romain Wolf, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Anette Von Matt, Ross Sinclair Strang, Alexander Baxter Smith, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Frank Stowasser, Nicola Tufilli
  • Publication number: 20160106753
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Applicant: Novartis AG
    Inventors: Giorgio CARAVATTI, Sylvie CHAMOIN, Pascal FURET, Klemens HOGENAUER, Konstanze HURTH, Christoph KALIS, Karen KAMMERTOENS, Ian LEWIS, Henrik MOEBITZ, Alexander Baxter SMITH, Nicolas SOLDERMANN, Romain WOLF, Frederic ZECRI
  • Publication number: 20150342951
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 3, 2015
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo Antonio FERNANDES GOMES DOS SANTOS, Pascal FURET, Christina HEBACH, Klemens HOGENAUER, Gregory HOLLINGWORTH, Christoph KALIS, Ian LEWIS, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frederic STAUFFER, Ross STRANG, Frank STOWASSER, Nicola TUFFILLI, Anette VON MATT, Romain WOLF, Frederic ZECRI
  • Publication number: 20140249139
    Abstract: The invention relates to substituted quinazoline derivative of the formula (I), wherein A, X1, X2, X3, X4 and R5 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Pascal Furet, Christina Hebach, Klemens Hogenauer, Gregory Hollingworth, Ian Lewis, Alexander Baxter Smith, Nicolas Solvermann, Frederic Stauffer, Romain Wolf, Frederic Zecri
  • Publication number: 20140128370
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Frédéric ZECRI, Nicolas SOLDERMANN, Romain WOLF, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Anette VON MATT, Ross Sinclair STRANG, Alexander Baxter SMITH, Paulo FERNANDES GOMES DOS SANTOS, Nadege GRAVELEAU, Frank STOWASSER, Nicola TUFILLI
  • Patent number: 8653092
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: February 18, 2014
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Högenauer, Gregory Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Strang, Nicola Tufilli, Anette Von Matt, Romain Wolf, Frédéric Zecri
  • Publication number: 20120065183
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo FERNANDES GOMES DOS SANTOS, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frank STOWASSER, Ross STRANG, Nicola TUFILLI, Anette VON MATT, Romain WOLF, Frédéric ZECRI
  • Publication number: 20070092527
    Abstract: This invention relates to the newly identified utility of certain G protein-coupled receptors (GPCRs), in particular to OGR1, GPR4 and TDAG8 (TDAG8 is also named GPR65) polypeptides, and polynucleotides encoding such GPCR polypeptides, to their use in diagnosis and to methods of identifying compounds that are agonists or antagonists to said GPCRs, and to the production of such polypeptides and polynucleotides.
    Type: Application
    Filed: June 18, 2004
    Publication date: April 26, 2007
    Applicant: NOVARTIS AG
    Inventors: Birgit Baumgarten, Carol Jones, Marie-Gabrielle Ludwig, Georg Martiny-Baron, Klaus Seuwen, Romain Wolf, Lorenza Wyder, Thomas Suply